Výsledky vyhledávání - "Müller, LME"

Plasmacytoid dendritic cells orchestrate innate and adaptive anti-tumor immunity induced by oncolytic coxsackievirus A21

Publikováno v: Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-16 (2019)
Journal for Immunotherapy of Cancer

Background The oncolytic virus, coxsackievirus A21 (CVA21), has shown promise as a single agent in several clinical trials and is now being tested in combination with immune checkpoint blockade. Combination therapies offer the best chance of disease

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::1d00c8a5a850c6ae6bef2b7864420855
http://link.springer.com/article/10.1186/s40425-019-0632-y

Zobrazit plný text záznamu

Akademický článek

Efficacy of coxsackievirus A21 against drug-resistant neoplastic B cells.

Autor: Holmes M; Leeds Institute of Medical Research, University of Leeds, Beckett Street, Leeds LS9 7TF, UK., Scott GB; Leeds Institute of Medical Research, University of Leeds, Beckett Street, Leeds LS9 7TF, UK., Heaton S; Leeds Institute of Medical Research, University of Leeds, Beckett Street, Leeds LS9 7TF, UK., Barr T; Leeds Institute of Medical Research, University of Leeds, Beckett Street, Leeds LS9 7TF, UK., Askar B; Leeds Institute of Medical Research, University of Leeds, Beckett Street, Leeds LS9 7TF, UK., Müller LME; Leeds Institute of Medical Research, University of Leeds, Beckett Street, Leeds LS9 7TF, UK., Jennings VA; Leeds Institute of Medical Research, University of Leeds, Beckett Street, Leeds LS9 7TF, UK.; The Institute of Cancer Research, Division of Radiotherapy and Imaging, Chester Beatty Laboratories, London SW3 6JB, UK., Ralph C; Leeds Institute of Medical Research, University of Leeds, Beckett Street, Leeds LS9 7TF, UK., Burton C; Haematological Malignancy Diagnostic Service, Leeds Teaching Hospitals, Beckett Street, Leeds LS9 7TF, UK., Melcher A; The Institute of Cancer Research, Division of Radiotherapy and Imaging, Chester Beatty Laboratories, London SW3 6JB, UK., Hillmen P; Leeds Institute of Medical Research, University of Leeds, Beckett Street, Leeds LS9 7TF, UK., Parrish C; St James's University Hospital, Leeds Teaching Hospital, Beckett Street, Leeds LS9 7TF, UK., Errington-Mais F; Leeds Institute of Medical Research, University of Leeds, Beckett Street, Leeds LS9 7TF, UK.

Publikováno v: Molecular therapy oncolytics [Mol Ther Oncolytics] 2023 Mar 24; Vol. 29, pp. 17-29. Date of Electronic Publication: 2023 Mar 24 (Print Publication: 2023).

Zobrazit plný text záznamu

Akademický článek

Reovirus-induced cell-mediated immunity for the treatment of multiple myeloma within the resistant bone marrow niche.

Autor: Müller LME; Division of Haematology and Immunology, Leeds Institute of Medical Research, University of Leeds, Leeds, UK., Migneco G; Division of Haematology and Immunology, Leeds Institute of Medical Research, University of Leeds, Leeds, UK., Scott GB; Division of Haematology and Immunology, Leeds Institute of Medical Research, University of Leeds, Leeds, UK., Down J; Sheffield Myeloma Research Team, Department of Oncology and Metabolism, University of Sheffield, Sheffield, UK., King S; Sheffield Myeloma Research Team, Department of Oncology and Metabolism, University of Sheffield, Sheffield, UK., Askar B; Division of Haematology and Immunology, Leeds Institute of Medical Research, University of Leeds, Leeds, UK., Jennings V; Division of Radiotherapy and Imaging, Institute of Cancer Research, London, UK., Oyajobi B; Cancer Therapy and Research Center, The University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA., Scott K; Division of Haematology and Immunology, Leeds Institute of Medical Research, University of Leeds, Leeds, UK., West E; Division of Haematology and Immunology, Leeds Institute of Medical Research, University of Leeds, Leeds, UK., Ralph C; Division of Haematology and Immunology, Leeds Institute of Medical Research, University of Leeds, Leeds, UK., Samson A; Division of Haematology and Immunology, Leeds Institute of Medical Research, University of Leeds, Leeds, UK., Ilett EJ; Division of Haematology and Immunology, Leeds Institute of Medical Research, University of Leeds, Leeds, UK., Muthana M; Sheffield Myeloma Research Team, Department of Oncology and Metabolism, University of Sheffield, Sheffield, UK., Coffey M; Oncolytics Biotech Inc, Calgary, Alberta, Canada., Melcher A; Division of Radiotherapy and Imaging, Institute of Cancer Research, London, UK., Parrish C; Department of Haematology, St James's University Hospital, Leeds, UK., Cook G; Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK., Lawson M; Sheffield Myeloma Research Team, Department of Oncology and Metabolism, University of Sheffield, Sheffield, UK., Errington-Mais F; Division of Haematology and Immunology, Leeds Institute of Medical Research, University of Leeds, Leeds, UK F.Errington@leeds.ac.uk.

Publikováno v: Journal for immunotherapy of cancer [J Immunother Cancer] 2021 Mar; Vol. 9 (3).

Zobrazit plný text záznamu